Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

uniQure N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LEXINGTON, MASS. AND AMSTERDAM, SEPT. 29, 2025 (GLOBE NEWSWIRE) -- UNIQURE N.V. (NASDAQ: QURE), A LEADING GENE THERAPY COMPANY ADVANCING TRANSFORMATIVE THERAPIES FOR PATIENTS WITH SEVERE MEDICAL NEEDS, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 6,736,841 ORDINARY SHARES AT A PUBLIC OFFERING PRICE OF $47.50 PER SHARE, WHICH INCLUDES 947,368 ORDINARY SHARES ISSUED PURSUANT TO THE EXERCISE IN FULL BY THE UNDERWRITERS OF THEIR OPTION TO PURCHASE ADDITIONAL ORDINARY SHARES IN THE OFFERING; AND, IN LIEU OF ORDINARY SHARES TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE 526,316 OF ITS ORDINARY SHARES AT THE PUBLIC OFFERING PRICE PER SHARE LESS THE $0.0001 PER SHARE EXERCISE PRICE OF EACH PRE-FUNDED WARRANT. THE AGGREGATE GROSS PROCEEDS TO UNIQURE FROM THE OFFERING, BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES PAYABLE BY UNIQURE, WERE APPROXIMATELY $345 MILLION. ALL SECURITIES IN THE OFFERING WERE SOLD BY UNIQURE.

UNIQURE ANNOUNCES CLOSING OF UPSIZED PUBLIC OFFERING AND FULL EXERCISE BY UNDERWRITERS OF OPTION TO PURCHASE ADDITIONAL SHARES

LEXINGTON, MASS. AND AMSTERDAM, SEPT. 25, 2025 (GLOBE NEWSWIRE) -- UNIQURE N.V. (NASDAQ: QURE), A LEADING GENE THERAPY COMPANY ADVANCING TRANSFORMATIVE THERAPIES FOR PATIENTS WITH SEVERE MEDICAL NEEDS, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 5,789,473 ORDINARY SHARES AT A PUBLIC OFFERING PRICE OF $47.50 PER SHARE, AND, IN LIEU OF ORDINARY SHARES TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE 526,316 OF ITS ORDINARY SHARES AT THE PUBLIC OFFERING PRICE PER SHARE LESS THE $0.0001 PER SHARE EXERCISE PRICE OF EACH PRE-FUNDED WARRANT. THE AGGREGATE GROSS PROCEEDS TO UNIQURE FROM THE OFFERING, BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES PAYABLE BY UNIQURE, ARE EXPECTED TO BE APPROXIMATELY $300 MILLION. ALL SECURITIES TO BE SOLD IN THE OFFERING ARE BEING SOLD BY UNIQURE. IN ADDITION, UNIQURE HAS GRANTED TO THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO 947,368 ADDITIONAL ORDINARY SHARES AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT SEPTEMBER 29, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

UNIQURE ANNOUNCES PRICING OF UPSIZED $300 MILLION PUBLIC OFFERING

LEXINGTON, MASS. AND AMSTERDAM, SEPT. 24, 2025 (GLOBE NEWSWIRE) -- UNIQURE N.V. (NASDAQ: QURE), A LEADING GENE THERAPY COMPANY ADVANCING TRANSFORMATIVE THERAPIES FOR PATIENTS WITH SEVERE MEDICAL NEEDS, TODAY ANNOUNCED THAT IT HAS COMMENCED A $200 MILLION UNDERWRITTEN PUBLIC OFFERING OF ITS ORDINARY SHARES AND, IN LIEU OF ORDINARY SHARES TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE ITS ORDINARY SHARES. ALL SECURITIES TO BE SOLD IN THE OFFERING WILL BE OFFERED BY UNIQURE. IN ADDITION, UNIQURE INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO A NUMBER OF ADDITIONAL ORDINARY SHARES EQUAL TO 15% OF THE TOTAL NUMBER OF ORDINARY SHARES (AND ORDINARY SHARES UNDERLYING PRE-FUNDED WARRANTS) SOLD IN THE PUBLIC OFFERING, ON THE SAME TERMS AND CONDITIONS. THE OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

UNIQURE ANNOUNCES $200 MILLION PROPOSED PUBLIC OFFERING

~ TERM OF CURRENT $50 MILLION DEBT OUTSTANDING EXTENDED FROM JANUARY 2027 TO OCTOBER 2030 ~ ~ ADDITIONAL $100 MILLION AVAILABLE SUBJECT TO REGULATORY AND FINANCIAL MILESTONES ~ ~ ADDITIONAL $25 MILLION AVAILABLE SUBJECT TO HERCULES' APPROVAL ~ ~ TRANSACTION PROVIDES FINANCIAL FLEXIBILITY AND IMPROVES COST OF CAPITAL ~ LEXINGTON, MASS. AND AMSTERDAM, SEPT.

UNIQURE ANNOUNCES REFINANCING OF EXISTING $50 MILLION DEBT AND SECURING UP TO AN ADDITIONAL $125 MILLION IN NON-DILUTIVE FUNDING

~ PIVOTAL STUDY MET PRIMARY ENDPOINT; HIGH-DOSE AMT-130 DEMONSTRATED STATISTICALLY SIGNIFICANT 75% DISEASE SLOWING AT 36 MONTHS AS MEASURED BY CUHDRS COMPARED TO A PROPENSITY SCORE-MATCHED EXTERNAL CONTROL ~

UNIQURE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE I/II STUDY OF AMT-130 IN PATIENTS WITH HUNTINGTON'S DISEASE

~ ALL PATIENTS IN THE FIRST COHORT ACHIEVED BETWEEN 27- TO 208-FOLD INCREASES IN -GAL A ACTIVITY RELATIVE TO MEAN NORMAL LEVEL ~

UNIQURE ANNOUNCES INITIAL AMT-191 PHASE I/IIA DATA SHOWING SUSTAINED INCREASES IN -GAL A ENZYME ACTIVITY IN PATIENTS WITH FABRY DISEASE

~ ACHIEVED ALIGNMENT WITH THE FDA ON THE AMT-130 STATISTICAL ANALYSIS PLAN AND CMC REQUIREMENTS TO SUPPORT A PLANNED BLA SUBMISSION IN THE FIRST QUARTER OF 2026;

UNIQURE ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS OF RECENT COMPANY PROGRESS

UNIQURE TO HOST EARNINGS CALL ON TUESDAY, JULY 29, 2025 AT 8:30 A.M. ET UNIQURE TO HOST EARNINGS CALL ON TUESDAY, JULY 29, 2025 AT 8:30 A.M. ET

UNIQURE TO ANNOUNCE SECOND QUARTER 2025 FINANCIAL RESULTS

~PROVEN BIOTECH EXECUTIVE TO LEAD COMMERCIALIZATION OF AMT-130 IN HUNTINGTON'S DISEASE ~ LEXINGTON, MASS. AND AMSTERDAM, JUNE 11, 2025 (GLOBE NEWSWIRE) -- UNIQURE N.V.

UNIQURE ANNOUNCES APPOINTMENT OF KYLIE O'KEEFE AS CHIEF CUSTOMER AND STRATEGY OFFICER

~ ALIGNMENT WITH FDA CONTINUES TO SUPPORT ACCELERATED APPROVAL PATHWAY ~ ~ BLA SUBMISSION PLANNED FOR FIRST QUARTER OF 2026 ~ ~ CONFERENCE CALL TODAY AT 8:30 A.M. ET ~ LEXINGTON, MASS.

uniQure N.V.

QURE

Price

Financials Overview

Financial Reports

No items found.

Press Releases

uniQure N.V.

QURE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

QURE